Isolated Limb Infusion for Recurrent and Locally Metastatic Limb Melanoma
- 824 Downloads
Recurrent and metastatic melanoma confined to a limb is a frequently encountered clinical problem in patients with initial primary limb melanoma. Regional chemotherapy using isolated limb perfusion (ILP) provides effective treatment, but is invasive, complex, and costly. Isolated limb infusion (ILI) chemotherapy is a simple, minimally invasive, and effective alternative to ILP.
ILI involves drug administration into a limb via percutaneously inserted catheters after vascular isolation of the limb with a tourniquet. The infused drugs, normally melphalan and actinomycin D, are circulated for 30 minutes via a simple extracorporeal circuit incorporating a heater to produce mild hyperthermia of the limb, but with no oxygenation.
Limb tumor remission rates following ILI are similar to those achieved by conventional ILP. ILI is well tolerated and, in contrast to ILP, elderly patients and those with major medical comorbidities and peripheral vascular disease can be treated with satisfactory results.
The development of effective systemic treatment options for patients with melanoma in the past decade has provided new melanoma therapy options. However, the response and control rates of ILI are still superior to those achieved following systemic therapy. Nevertheless, there is great potential value in combining regionally applied ILI with systemically administered agents to achieve an optimal and sustained response, and clinical trials of combined regional and systemic therapies are in progress.
KeywordsMelanoma Metastasis Extremity Unresectable Isolated limb infusion Melphalan Actinomycin D
- 3.Schraffordt Koops H, Lejeune FJ, Kroon BBR, Klaase JM, Hoekstra HJ. Isolated limb perfusion for melanoma: technical aspects. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004. p. 404–9.Google Scholar
- 8.Bland KI, Kimura AK, Brenner DE, et al. A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg. 1989;209:73–80.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Thompson JF, Waugh RC, Saw RP, Kam PC. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92.Google Scholar
- 16.Beasley G, Kroon HM, Ross M, Kam PCA, Thompson JF, Tyler D. Isolated limb infusion for melanoma (Chapter 27). In: Balch C, Houghton AN, Sober AJ, Soong SJ, Atkins MB, Thompson FJ, editors. Cutaneous melanoma. 5th ed. St. Louis, MO: Quality Medical Publishing Inc.; 2009. p. 541–60. ISBN: 978-1-57626-276-4.Google Scholar
- 17.Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. EORTC Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998;16:2906–12.CrossRefPubMedGoogle Scholar
- 18.Kroon HM, Coventry BJ, Giles MH, Henderson MA, Speakman D, Wall M, Barbour A, Serpell J, Paddle P, Smithers BM, Thompson JF. Safety and efficacy of isolated limb infusion chemotherapy for advanced locoregional melanoma in elderly patients: an Australian multicenter study. Ann Surg Oncol. 2017;24:3245–51.CrossRefPubMedGoogle Scholar
- 29.Thompson JF, Ramzan I, Kam PCA, Yau DF. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat. 1996;9:13–6.Google Scholar
- 45.World Health Organization. WHO handbook for reporting results of cancer treatments (WHO offset publication no. 48). Geneva: World Health Organization; 1979.Google Scholar
- 51.Beasley GM, Sharma K, Wong J, Miller M, Turley RS, Lidsky M, Masoud M, Dewhirst MW, Mosca PJ, Zager JS, Tyler DS. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer. 2012;118:6136–43.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Beasley GM, Speicher P, Augustine CK, et al. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Ann Surg Oncol. 2015;22:287–94.CrossRefPubMedGoogle Scholar
- 63.Marsden J, Samarasinghe V, Duddy M, et al. Regional chemotherapy for inoperable limb cancer using isolated limb infusion. Br J Dermatol. 2008;159:10.Google Scholar
- 66.Coventry BJ, Kroon HM, Giles MH, Henderson M, Speakman D, Wall M, Barbour A, Serpell J, Paddle P, Coventry AG, Sullivan T, Smithers BM. Multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. J Surg Oncol. 2014;109:780–5.CrossRefPubMedGoogle Scholar